The Impact of the Management Strategies for Patients with Subclinical Hypothyroidism on Long-term Clinical Outcomes: An Umbrella Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 May 19

PMID 35587500

Authors

Brenda S Bauer

Amaya Azcoaga-Lorenzo

Utkarsh Agrawal

Adeniyi Francis Fagbamigbe

Colin McCowan

Affiliations

Soon will be listed here.

Abstract

Aim: This umbrella review summarises and compares synthesised evidence on the impact of subclinical hypothyroidism and its management on long-term clinical outcomes.

Methods: We conducted comprehensive searches on MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, JBI Evidence Synthesis, the PROSPERO register, Epistemonikos Database and PDQ Evidence from inception to February and July 2021 using keywords on subclinical hypothyroidism, treatment with levothyroxine, monitoring and primary outcomes (all-cause mortality, cardiovascular events, stroke, frailty fractures and quality of life). Only systematic reviews and meta-analyses on adult patient populations were considered. Study selection, data extraction and quality appraisal using AMSTAR-2 were done independently by two reviewers and discrepancies were resolved through discussion. Overlap across the selected reviews was also assessed, followed by a narrative synthesis of findings.

Results: A total of 763 studies were identified from literature searches; 20 reviews met inclusion criteria. Methodological quality ratings were high (n = 8), moderate (n = 7), and low (n = 5), but no reviews were excluded on this basis. Though there was slight overlap across all reviews, some pairwise comparisons had high corrected covered area scores. Compared to euthyroidism, untreated subclinical hypothyroidism was associated with a higher risk of cardiovascular events or death if Thyroid Stimulating Hormone was above 10mIU/L at baseline. Treatment was associated with a lower risk of death from all causes for patients younger than 70 years and possibly better cognitive and quality of life scores than untreated individuals. Evidence on the risk of strokes and fractures was inconclusive.

Conclusion: In the long term, treatment of subclinical hypothyroidism may be beneficial for some patient groups. However, the findings of this review are negatively impacted by the relative sparseness and poor quality of available evidence. Additional large and adequately powered studies are needed to investigate this topic further.

Systematic Review Registration: PROSPERO (CRD42021235172).

Citing Articles

When Should the Treatment of Obesity in Thyroid Disease Begin?.

Sutkowska E, Kisiel M, Zubkiewicz-Kucharska A Biomedicines. 2025; 13(1).

PMID: 39857741 PMC: 11760466. DOI: 10.3390/biomedicines13010157.

Exploring the causal factor effects of hypothyroidism on ischemic stroke: a two-sample Mendelian randomization study.

Tian Y, Shi X, Shui J, Liu X, Bu Y, Liu Y Front Neurol. 2024; 15:1322472.

PMID: 38361639 PMC: 10868650. DOI: 10.3389/fneur.2024.1322472.

The Western and Chinese exercise training for blood pressure reduction among hypertensive patients: An overview of systematic reviews.

Tsoi K, Lam A, Tran J, Hao Z, Yiu K, Chia Y J Clin Hypertens (Greenwich). 2023; 26(12):1327-1341.

PMID: 36946438 PMC: 11654863. DOI: 10.1111/jch.14610.

References

Blum M, Bauer D, Collet T, Fink H, Cappola A, da Costa B . Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20):2055-65. PMC: 4729304. DOI: 10.1001/jama.2015.5161. View

Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. PMC: 5833365. DOI: 10.1136/bmj.j4008. View

Du Puy R, Poortvliet R, Mooijaart S, den Elzen W, Jagger C, Pearce S . Outcomes of Thyroid Dysfunction in People Aged Eighty Years and Older: An Individual Patient Data Meta-Analysis of Four Prospective Studies (Towards Understanding Longitudinal International Older People Studies Consortium). Thyroid. 2020; 31(4):552-562. DOI: 10.1089/thy.2020.0567. View

Bauer B, Azcoaga-Lorenzo A, Agrawal U, McCowan C . Management strategies for patients with subclinical hypothyroidism: a protocol for an umbrella review. Syst Rev. 2021; 10(1):290. PMC: 8561963. DOI: 10.1186/s13643-021-01842-y. View

Hennessy E, Johnson B . Examining overlap of included studies in meta-reviews: Guidance for using the corrected covered area index. Res Synth Methods. 2019; 11(1):134-145. PMC: 8555740. DOI: 10.1002/jrsm.1390. View

Razvi S, Shakoor A, Vanderpump M, Weaver J, Pearce S . The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab. 2008; 93(8):2998-3007. DOI: 10.1210/jc.2008-0167. View

Gates M, Gates A, Duarte G, Cary M, Becker M, Prediger B . Quality and risk of bias appraisals of systematic reviews are inconsistent across reviewers and centers. J Clin Epidemiol. 2020; 125:9-15. DOI: 10.1016/j.jclinepi.2020.04.026. View

Collet T, Bauer D, Cappola A, Asvold B, Weiler S, Vittinghoff E . Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. J Clin Endocrinol Metab. 2014; 99(9):3353-62. PMC: 4154087. DOI: 10.1210/jc.2014-1250. View

Santaguida P, Keshavarz H, Carlesso L, Lomotan M, Gross A, MacDermid J . A description of the methodology used in an overview of reviews to evaluate evidence on the treatment, harms, diagnosis/classification, prognosis and outcomes used in the management of neck pain. Open Orthop J. 2013; 7:461-72. PMC: 3793583. DOI: 10.2174/1874325001307010461. View

10.

Singh S, Duggal J, Molnar J, Maldonado F, Barsano C, Arora R . Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol. 2007; 125(1):41-8. DOI: 10.1016/j.ijcard.2007.02.027. View

11.

Lunny C, Pieper D, Thabet P, Kanji S . Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol. 2021; 21(1):140. PMC: 8265144. DOI: 10.1186/s12874-021-01269-y. View

12.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

13.

Helfand M, Redfern C . Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med. 1998; 129(2):144-58. DOI: 10.7326/0003-4819-129-2-199807150-00020. View

14.

Cooper D, Biondi B . Subclinical thyroid disease. Lancet. 2012; 379(9821):1142-54. DOI: 10.1016/S0140-6736(11)60276-6. View

15.

Klaver E, van Loon H, Stienstra R, Links T, Keers J, Kema I . Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. Thyroid. 2013; 23(9):1066-73. PMC: 3770241. DOI: 10.1089/thy.2013.0017. View

16.

Rodondi N, den Elzen W, Bauer D, Cappola A, Razvi S, Walsh J . Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010; 304(12):1365-74. PMC: 3923470. DOI: 10.1001/jama.2010.1361. View

17.

Rugge J, Bougatsos C, Chou R . Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 162(1):35-45. DOI: 10.7326/M14-1456. View

18.

Surks M, Goswami G, Daniels G . The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005; 90(9):5489-96. DOI: 10.1210/jc.2005-0170. View

19.

Perry R, Whitmarsh A, Leach V, Davies P . A comparison of two assessment tools used in overviews of systematic reviews: ROBIS versus AMSTAR-2. Syst Rev. 2021; 10(1):273. PMC: 8543959. DOI: 10.1186/s13643-021-01819-x. View

20.

Aromataris E, Fernandez R, Godfrey C, Holly C, Khalil H, Tungpunkom P . Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015; 13(3):132-40. DOI: 10.1097/XEB.0000000000000055. View